RnRMarketResearch.com adds Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth in its store.
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology.
Complete report is available at http://www.rnrmarketresearch.com/large-cap-pharma-us-eu-outlook-2016-maximizing-their-strength-on-fewer-therapy-class-personalized-medicine-novel-target-and-biosimilars-for-future-growth-market-report.html.
Bristol-Myers's with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, there's Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field. The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche' in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer's disease, Parkinson's, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain). Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I).
Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig. First - in-class mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies - more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines. Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.
Purchase a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=516351.
Amgen, Biogen Idec, Celgene, Gilead, AstraZeneca, GlaxoSmithKline, Merck, Merck KGaA, Novartis, Novo Nordisk
List of Tables
KEY MILESTONES (AMGN)
Data Block ( AMGN)
KEY MILESTONES (CELG)
Data Block ( CELG)
Table 1 : CELGENE -
RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RECENTLY APPROVED - DATA COMPARISON
Data Block ( BIIB)
KEY MILESTONES (BIIB)
ANNEXURE: Biogen Idec
MULTIPLE SCLEROSIS - INJECTABLE DRUGS DATA COMPARISON
Table 1 :Gilead Sciences
Table 2 :Gilead Sciences
DATA FROM ASTRAL -1 STUDY
Table 3 :Gilead Sciences
DATA FROM ASTRAL-4 STUDY
Key Milestones ( GILD)
Data Block ( GSK)
KEY MILESTONES (GSK)
Data Block Merck & Co. ( MRK)
Table 1 :Merck
KEYTRUDA: LIST OF ON-GOING COMBINATION STUDIES
Table 2 :Merck
DATA FROM C-CREST 1 & 2 PART A STUDYKEY MILESTONES (MRK)
Data Block : Merck KGaA
MILESTONE TABLE (MRK.EU)
Data Block ( NVS)
Table 1 :Novartis
DATA FROM PHIII STUDY OF BUPARLISIB IN BREAST CANCER (BELLE-2)
Table 2 :Novartis
EFFICACY DATA OF LCZ696 IN PARADIGM-HF
Table 3 :Novartis
SANDOZ BIOSIMILAR PIPELINE STATUS
KEY MILESTONES (NVS)
Data Block (NOVOB)
Table 1 :Novo Nordisk
SELECTED LONG-ACTING rFVIII AND rFIX PRODUCTS
KEY MILESTONES (NOVOB)
List of Figures
IMPACT OF BLINATUMOMAB TREATMENT IN MRD+ ALL PTS
Figure 1 :Novo Nordisk KEY FEATURES OF COMPOUNDS IN PHASE 1 VELOPMENT FOR OBESITY
Get a DISCOUNT at http://www.rnrmarketresearch.com/contacts/discount?rname=516351.
RnR Market Research
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
P: + 1 888 391 5441